Back to results
US 10,238,672 B2Granted
Dosage forms for oral administration of zoledronic acid or related compounds for treating disease
AssigneeAntecip Bioventures II LLC
InventorHerriot Tabuteau
Life of this patent
Estimating the term…
Abstract
Oral dosage forms of osteoclast inhibitors, such as zoledronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions.
Claims30
A method of delivering zoledronic acid to the blood of a human being, comprising:
- administering an oral dosage form comprising zoledronic acid in a salt form to the human being in need of treatment with zoledronic acid, wherein the human being fasts for at least 4 hours prior to receiving the oral dosage form and the human being fasts for at least 4 hours after receiving the oral dosage form, wherein the bioavailability of zoledronic acid in the oral dosage form is about 1.4% to about 2%, and wherein a weekly oral dose of about 30 mg to about 100 mg of the zoledronic acid in the salt form is orally administered to the human being, and the zoledronic acid in the salt form is administered for a total of about 1 month to about 2 months.
A method of delivering zoledronic acid to the blood of a human being, comprising:
- administering an oral dosage form comprising zoledronic acid in a salt form to the human being in need of treatment with zoledronic acid, wherein the human being fasts for at least 4 hours prior to receiving the oral dosage form and the human being fasts for at least 4 hours after receiving the oral dosage form, wherein the bioavailability of zoledronic acid in the oral dosage form is about 1.4% to about 2%, and wherein about 50 mg/m2 to about 200 mg/m2 of the zoledronic acid in the salt form is orally administered to the human being within a month of about 28 days, and the zoledronic acid in the salt form is administered for a total of about 1 month to about 2 months.
A method of delivering zoledronic acid to the blood of a human being, comprising:
- administering an oral dosage form comprising zoledronic acid in an acid form to the human being in need of treatment with zoledronic acid, wherein the human being fasts for at least 4 hours prior to receiving the oral dosage form and the human being fasts for at least 4 hours after receiving the oral dosage form, wherein the bioavailability of zoledronic acid in the oral dosage form is about 1.4% to about 2%, and wherein a weekly oral dose of about 30 mg to about 100 mg of the zoledronic acid in the acid form is orally administered to the human being, and the zoledronic acid in the acid form is administered for a total of about 1 month to about 2 months.
A method of delivering zoledronic acid to the blood of a human being, comprising:
- administering an oral dosage form comprising zoledronic acid in an acid form to the human being in need of treatment with zoledronic acid, wherein the human being fasts for at least 4 hours prior to receiving the oral dosage form and the human being fasts for at least 4 hours after receiving the oral dosage form, wherein the bioavailability of zoledronic acid in the oral dosage form is about 1.4% to about 2%, and wherein about 50 mg/m2 to about 200 mg/m2 of the zoledronic acid in the acid form is orally administered to the human being within a month of about 28 days, and the zoledronic acid in the acid form is administered for a total of about 1 month to about 2 months.
Dependencies are inferred from the claim text.